Trial Profile
Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dornase alfa (Primary) ; Alteplase
- Indications Empyema
- Focus Therapeutic Use
- Acronyms DTPA
- 03 Feb 2020 Primary endpoint has not been met. (Time to hospital discharge)
- 03 Feb 2020 Results assessing effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema, published in the JAMA Pediatrics
- 20 Dec 2017 Status changed from recruiting to completed.